Discontinuation and reinitiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction. [PDF]
Landucci L +6 more
europepmc +1 more source
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death across cardio-kidney-metabolic diseases: A meta-analysis of randomized clinical trials. [PDF]
Marques P, Zannad F, Ferreira JP.
europepmc +1 more source
Aldosterone's impact on kidney health: exploring the benefits of mineralocorticoid receptor antagonists for renal protection. [PDF]
Liu Z +7 more
europepmc +1 more source
Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS). [PDF]
Richard EL +9 more
europepmc +1 more source
Efficacy of Mineralocorticoid Receptor Antagonists on Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: An Umbrella Review. [PDF]
Amornritvanich P +4 more
europepmc +1 more source
Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review. [PDF]
Miyasako K, Maeoka Y, Masaki T.
europepmc +1 more source
Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models. [PDF]
Varda L +4 more
europepmc +1 more source
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease: Clinical Evidence and Potential Adverse Events. [PDF]
Upadhyay A, Haider L.
europepmc +1 more source
Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis. [PDF]
Adji AS, Widjaja JS, de Liyis BG.
europepmc +1 more source
Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation. [PDF]
Rroji M +3 more
europepmc +1 more source

